Q1 2024 Evolus Inc Earnings Call Transcript
Key Points
- Evolus Inc (EOLS) reported a strong revenue growth of 42% year-over-year, with first quarter revenue reaching $59.3 million.
- The company added over 700 new purchasing accounts in the U.S., increasing the total number of customers to over 13,000, representing approximately 40% market penetration.
- Evolus Inc (EOLS)'s consumer loyalty program achieved an all-time high in redemptions, with approximately 180,000 consumers receiving treatment, 60% of whom were repeat treatments.
- The company is on track to achieve profitability by the fourth quarter of 2024, with operating expense growth maintained at less than half the rate of revenue growth.
- Evolus Inc (EOLS) is preparing for international expansion and product diversification, including launching in Australia and Spain, and introducing a novel dermal filler line in 2025.
- Despite strong U.S. sales, international revenue remains a small fraction, with over 95% of total revenues coming from the U.S. market.
- The company reported a non-GAAP loss from operations of $0.9 million for the first quarter, although this was an improvement from the previous quarter.
- Evolus Inc (EOLS) faces increasing competition in the neurotoxin market, with new entrants expected to challenge market dynamics.
- The company's reliance on the performance of Jeuveau poses risks if market dynamics shift unfavorably or if new products fail to meet expectations.
- While the company has a strong cash position, it noted the use of proceeds from a recent offering to potentially pursue strategic opportunities, which introduces uncertainty regarding future capital allocation.
Good afternoon, everyone, and thank you for standing by, and welcome to the Evolus First Quarter 2024 earnings conference call. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, today's conference is being recorded and webcast live and all participants are in a listen only mode. After the speakers' remarks there will be a question and answer session. I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator, and welcome to everyone joining us on today's call to review Avalara's First Quarter 2024 financial results. Our first quarter 2024 press release is now on our website at Edwards.com. With me today are David Moatazedi, President and Chief Executive Officer, and Sandra Beaver, Chief Financial Officer. We have our Chief Medical Officer and Head of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
